Transcriptomic analyses of patient peripheral blood with hemoglobin depletion reveal glioblastoma biomarkers. Academic Article uri icon

Overview

abstract

  • Peripheral blood is gaining prominence as a noninvasive alternative to tissue biopsy to develop biomarkers for glioblastoma (GBM); however, widely utilized blood-based biomarkers in clinical settings have not yet been identified due to the lack of a robust detection approach. Here, we describe the application of globin reduction in RNA sequencing of whole blood (i.e., WBGR) and perform transcriptomic analysis to identify GBM-associated transcriptomic changes. By using WBGR, we improved the detection sensitivity of informatic reads and identified differential gene expression in GBM blood. By analyzing tumor tissues, we identified transcriptomic traits of GBM blood. Further functional enrichment analyses retained the most changed genes in GBM. Subsequent validation elicited a 10-gene panel covering mRNA, long noncoding RNA, and microRNA (i.e., GBM-Dx panel) that has translational potential to aid in the early detection or clinical management of GBM. Here, we report an integrated approach, WBGR, with comprehensive analytic capacity for blood-based marker identification.

publication date

  • January 25, 2023

Identity

PubMed Central ID

  • PMC3412702

Scopus Document Identifier

  • 85146831078

Digital Object Identifier (DOI)

  • 10.1038/s41525-022-00348-3

PubMed ID

  • 36697401

Additional Document Info

volume

  • 8

issue

  • 1